The aim of this study (ClinicalTrials.gov, NCT01744470) was to determine the efficacy and safety of two different doses of extended-release tacrolimus (TacER) in kidney transplant recipients (KTRs) between 4 and 12 mo after transplantation. Stable steroid-free KTRs were randomized (1:1) after 4 mo: Group A had a 50% reduction in TacER dose with a targeted TacER trough level (C 0 ) >3 lg/L; group B had no change in TacER dose (TacER C 0 7-12 lg/L). The primary outcome was estimated GFR at 1 year. Of 300 patients, the intent-to-treat analysis included 186 patients (group A, n = 87; group B, n = 99). TacER C 0 was lower in group A than in group B at 6 mo (4.1 AE 2.7 vs. 6.7 AE 3.9 lg/L, p < 0.0001) and 12 mo (5.6 AE 2.0 vs. 7.4 AE 2.1 lg/L, p < 0.0001). Estimated GFR was similar in both groups at 12 mo (group A, 56.0 AE 17.5 mL/min per 1.73 m²; group B, 56.0 AE 22.1 mL/min per 1.73 m²). More rejection episodes occurred in group A than group B (11 vs. 3; p = 0.016). At 1 year, subclinical inflammation occurred more frequently in group A than group B (inflammation score [i] >0: 21.4% vs. 8.8%, p = 0.047; tubulitis score [t] >0: 19.6% vs. 8.7%, p = 0.076; i + t: 1.14 AE 1.21 vs. 0.72 AE 1.01, p = 0.038). Anti-HLA donor-specific antibodies appeared only in group A (6 vs. 0 patients, p = 0.008). TacER C 0 should be maintained >7 lg/L during the first year after transplantation in low-immunological-risk, steroid-free KTRs receiving a moderate dose of mycophenolic acid.
Abbreviations: aah, arteriolar hyaline thickening; ABMR, antibody-mediated rejection; BPAR, biopsyproven acute rejection; BR, before randomization; C 0 , trough level; cg, glomerular double contours; ci, interstitial fibrosis; CMV, cytomegalovirus; CNI, calcineurin inhibitor; ct, tubular atrophy; cv, fibrous intimal thickening; DGF, delayed graft function; DSA, donor-specific antibody; EC-MPS, enteric-coated mycophenolate sodium; eGFR, estimated GFR; ESRD, end-stage renal disease; g, glomerulitis; HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; i, inflammation; IF/TA, interstitial fibrosis/tubular atrophy; KTR, kidney transplant recipient; M, month; MMF, mycophenolate mofetil; mTOR, mammalian target of rapamycin; NS, not significant; PR, just after randomization; ptc, peritubular capillaritis; PTDM, posttransplant diabetes mellitus; t, tubulitis; TacER, extended-release
Introduction
Renal transplantation is the treatment of choice for patients with end-stage renal disease (1) . Generalization of maintenance immunosuppressive strategies based on calcineurin inhibitors (CNIs) has been an essential determinant of progress. This is mainly because of the drastic reduction in the incidence of acute rejection episodes, which remain associated with poorer graft outcome and subsequent appearance of anti-HLA donor-specific antibodies (DSAs) (2, 3) . Tacrolimus has progressively replaced cyclosporine (4) , and up to 90% of kidney transplant recipients (KTRs) transplanted in the United States in 2012 received a combination of tacrolimus and mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS).
Tacrolimus has a narrow therapeutic index, and its use requires individual dose titration to minimize the risk of dose-related toxicity while maintaining a high level of efficacy. Surprisingly, the trough concentrations of tacrolimus have not been clearly defined to date. Maintaining high dosages of tacrolimus has been withdrawn (5), but minimization strategies to limit chronic renal toxicity and to reduce the risk of overimmunosuppression have not been clarified. The Symphony study was the largest clinical trial to assess the impact of reduced exposure to CNIs in KTRs (6) . The results at 1 year regarding acute rejection and graft function were excellent for patients randomized in the low-tacrolimus arm while maintained on steroids. Unfortunately, the targeted trough tacrolimus concentrations in the protocol (3-7 lg/L) were slightly different from those really obtained (close to 7 lg/L). Consequently, this study could not establish a precise target for trough tacrolimus concentrations in low-risk renal graft recipients. It can, however, explain why the target trough concentrations for tacrolimus in more recent trials have sometimes been very wide (7, 8) , particularly beyond the third month after transplantation.
Extended-release tacrolimus (TacER) formulations have been developed to improve treatment compliance and possibly improve graft outcome, with good efficacy and tolerance profiles at 1 and 4 years after transplantation (9, 10) . In this large study, however, the target for trough tacrolimus concentrations beyond 90 days was very wide (5-15 lg/L). The aim of the study reported in this paper was to determine the balance of efficacy and safety for two different trough concentrations of TacER in lowimmunological-risk KTRs between 4 and 12 mo after transplantation.
Patients and Methods

Study design and patients
We performed a prospective, open-label, randomized, multicenter, phase IV, parallel-group trial in 16 French transplant units (ClinicalTrials.gov, NCT01744470). The study protocol was approved by the ethics committee of Tours University Hospital in France. All patients provided informed written consent. The trial was performed in accordance with the principles of good clinical practice and the Declaration of Helsinki.
Eligible patients were adults (aged 18-70 years) scheduled to receive a first non-HLA identical single-organ renal transplant from either a living or deceased donor (except for donation after cardiac death). The major exclusion criteria were receipt of another organ, a positive B or T cell complement-dependent lymphocytotoxic cross-match with historic or current sera, presence of DSAs before transplantation (median fluorescence intensity threshold of 1000), BMI >35, active hepatitis B or hepatitis C infection, human immunodeficiency virus infection, total white blood cell count <2.5 9 10 9 /L, and a history of malignancy (except localized nonmelanocytic skin cancer).
All patients received basiliximab induction (20 mg on days 0 and 4). During the first 3 mo after transplantation, all patients received the same maintenance immunosuppressive regimen combining tacrolimus, MMF, or EC-MPS and steroids. The initial dose of tacrolimus was 0.2 mg/kg per day, adjusted to targeted trough tacrolimus levels between 8 and 12 lg/L. Tacrolimus could be introduced in the form of either TacER or an immediate-release formulation, but in the latter case, the conversion to TacER had to be occur <1 mo after transplantation. The initial doses of MMF and EC-MPS were 2000 and 1440 mg/day, respectively. After a pretransplant infusion of 500 mg methylprednisolone, steroids were given according to local practice. Progressive tapering was planned, and they were to be discontinued not later than 10 weeks after transplantation, except for patients who received steroids before transplantation.
Randomization (1:1) was stratified by center and achieved by use of a centralized, computer-generated, interactive, Web-response system. It was performed at 4 mo after transplantation, except in patients who presented one of the following criteria: episode of biopsy-proven acute rejection (BPAR), ≥30% increase in serum creatinine concentration during the previous 30 days, protein:creatinine ratio >1 g/g, MMF daily dose <1 g (<720 mg/day for EC-MPS), BK viremia, and appearance of DSAs after transplantation (systematically assessed at 3 mo after transplantation).
Patients were randomized to between 50% reduction in the daily dose of TacER (targeted TacER trough level [C 0 ] >3 lg/L; group A) or continuation of the prerandomization dose (targeted TacER C 0 7-12 lg/L; group B). A protocol biopsy was recommended 1 year after transplantation whenever possible.
Study end points
The primary efficacy end point was the crude difference in renal function at 1 year after transplantation, estimated according to the GFR using the MDRD formula (11) . Changes in renal function between 4 mo and 1 year were analyzed and compared in each group.
The secondary efficacy end points were the incidence of the following events within 8 mo after the randomization date: death, graft failure, BPAR scored according to the Banff classification (12) , and the appearance of DSAs (systematically assessed 1 year after transplantation). It is of note that BPAR includes minimal changes and subclinical rejections reported on a 1-year protocol biopsy. The safety assessment focused on the risk of developing posttransplant diabetes mellitus (PTDM; defined as fasting plasma glucose levels ≥8 mmol/L or glycosylated hemoglobin >6.5%), arterial hypertension (defined by use of antihypertensive drugs or systolic/diastolic arterial pressure >140/ 90 mmHg), and infections, especially BK viremia.
Statistical analysis
We hypothesized that the estimated GFR (eGFR) at 1 year after transplantation in group B would be 58 AE 15 mL/min (9) or higher after reduction of the TacER dose, with a difference of at least 7 mL/min between the two groups. Based on these assumptions and a rate of nonrandomization of 32%, the protocol called for enrollment of 286 patients to provide power of 90% with a type I error of 5%. In an amendment to the protocol, the number of patients was increased to 300 because transplantations were not performed in some enrolled patients.
Qualitative data were compared using the chi-square or Fisher exact test when a value in one group was less than five. Quantitative data were compared using the Mann-Whitney test. Efficacy and safety analyses were performed using a modified intent-to-treat population of all randomized patients who received at least one dose of the study drug. In addition, a per-protocol analysis was performed. A missing at random model was used to assess the primary outcome, including predicted eGFR in deceased patients (n = 1), return to dialysis (n = 1), and lack of data (n = 2). Patient survival, graft survival, and incidence of rejection were analyzed using Kaplan-Meier plots, and treatment groups were compared for day 365 data using the log-rank test censoring patients at the time of last follow-up. Statistical analyses were performed using SAS v9.4 (SAS Institute, Cary, NC), and p < 0.05 was considered significant.
Results
Patients
Between September 2012 and June 2014, 300 KTRs were recruited, and 188 of those were randomized ( Figure 1 ). Two patients in group A did not receive the study treatment and thus were excluded from the modified intent-to-treat analysis (n = 186). The groups were well balanced with respect to donor and recipient characteristics before transplantation (Table 1) ; however, polycystic kidney disease occurred more frequently in group A (p = 0.006). At randomization, eGFR was not different in either group (group A: 50.4 AE 16.0 mL/min per 1.73 m²; group B: 51.9 AE 18.2 mL/min per 1.73 m, p = 0.841). Overall, 72% of patients received MMF and 28% received EC-MPS. Doses were similar in both groups. A few patients remained on steroids at randomization (group A, n = 6; group B, n = 5).
Immunosuppressive treatment
Target trough levels for TacER were met throughout the study period ( Figure 2 ). As expected, the daily doses of tacrolimus and TacER C 0 were similar in both groups at almost all time points before randomization, particularly just before randomization. At 4 mo after transplantation, , whereas only six patients had proteinuria >0.5 g/day (group A, n = 2; group B, n = 4).
Risk of acute rejection was higher after tacrolimus reduction In total, 13 BPARs were reported after randomization (interval after randomization: 4.2 AE 3.3 mo), of which 10 were clinically suspected; three were subclinical rejections diagnosed on protocol biopsy performed at 1 year after transplantation. Overall, 92% of these were T cell-mediated rejections (TCMRs): five were borderline, five were grade I (two were IA and three were IB) and two were grade II, and one was an antibody-mediated rejection (ABMR). Of the subclinical rejections, two were borderline and one was grade IIB.
As shown in Figure 4A , the incidence of BPAR was higher in group A than group B (log-rank, p = 0.016). In addition, the risk of clinical rejection was higher in group A than group B (log-rank, p = 0.034) ( Figure 4B ). The details regarding rejections are reported in Table 2 . All TCMRs observed in group B corresponded to minimal changes, whereas 77% of TCMRs were grade I/II in group A. TCMRs were thus more severe in group A. It is of note that the difference between the two curves was gradual and increased at the end of the study because all subclinical rejections occurred in group A. In particular, no patients dropped out after randomization when the TacER daily dose was drastically reduced (median interval between randomization and rejection in group A was 4.6 AE 3.4 mo).
We assessed immunosuppressive treatments at the time of the rejection. First, no patient was receiving steroids. Second, mean MMF/EC-MPS dose was 1308 AE 522 mg/ day, according to the dose reported for all patients at 4 mo (1435 AE 550 mg/day) and 12 mo (1235 AE 508 mg/ day). Third, dose and trough tacrolimus levels at the time of the rejection in low tacrolimus group were 3.6 AE 1.5 g/day and 4.9 AE 1.3 lg/L, respectively.
The results of the 1 year protocol biopsy are reported in 1278 AE 506 mg/day, t = 0: 1269 AE 504 mg/day; p = 0.846) and tubulitis (t > 0: 1176 AE 513, i = 0: 1285 AE 502 mg/day, p = 0.427). Importantly, the proportion of patients with interstitial fibrosis/tubular atrophy (IF/TA) was similar in both groups.
DSAs appeared more frequently after reduction of tacrolimus DSAs appeared after randomization in six of 87 patients in group A with a functioning graft at the end of the study, whereas no patient in group B developed DSAs (p = 0.008). Importantly, a previous episode of rejection was reported in only one of six recipients with de novo DSA. Five of six patients with de novo DSAs had class II DSAs, and two had class I DSAs (one patient had both class I and class II DSAs). One ABMR occurred in group A, characterized by linear and intense C4d deposits in peritubular capillaries and interstitial hemorrhage. One nonimmunized patient in group B developed subclinical rejection characterized by glomerulitis (g) and peritubular capillaritis (ptc; g + ptc = 3) without C4d deposits or signs of cellular rejection.
Safety
Overall, 489 and 592 events were recorded in groups A and B, respectively. Adverse events were reported by 90.8% of patients in group A compared with 94.9% in group B (p = 0.118). Most were mild or moderate. The percentages of serious adverse events found in both groups were also similar (group A, 21.3%; group B, 22.2%; p = 0.885).
The most relevant data concerning safety are shown in Table 4 . In terms of infection, we focused on the risk of BK viremia. Two patients in each group were positive for BK viremia for the first time at the day of randomization. Thereafter, reactivation of BK virus tended to be more frequent in group B than group A (6.1% vs. 1.1%, respectively; p = 0.122). At the end of the study, only one patient in each group remained viremic, and no case of BK nephropathy was diagnosed. The incidence of cytomegalovirus (CMV) viremia after randomization was similar in both groups, and only two cases of CMV disease occurred. As reported in Table 4 , PTDM tended to occur more frequently in group B, but most cases occurred before randomization, and PTDM was eventually recorded in only two patients in each group between 4 and 12 mo after transplantation.
Discussion
We demonstrated that reduction of the daily TacER dose did not improve graft function after transplantation either at 6 or 12 mo, whereas mean TacER C 0 levels were significantly lower at these two points (5.3 and 5.6 lg/L, respectively). It could be expected that the reduction in daily TacER dose would lead to an immediate improvement in renal graft function because it is well known that CNIs cause vasoconstriction of the afferent and efferent glomerular arterioles (13) and that this renal failure mechanism depends on the dose of CNI. This vascular effect, for instance, was observed as soon as CNI was withdrawn in the Concept and Zeus studies, in which CNIs were replaced by mammalian target of rapamycin (mTOR) inhibitors for the first 6 mo after transplantation (14, 15) . More important, sustained significant reduction of exposure to TacER did not lead to better graft function 8 mo after reduction of the daily dose of tacrolimus, in agreement with similar chronic histological damage at 1 year after transplantation. Again, the result of reduction of CNI exposure seems to have been different to that obtained after CNI withdrawal (14, 15) . Two differences should be emphasized. First, all randomized clinical trials that assessed early switching from CNIs to mTOR inhibitors included cyclosporin, whereas no study has been designed with tacrolimus, particularly once-daily tacrolimus. Vascular effects, however, have usually been considered to be a class effect and not different between tacrolimus and cyclosporin. In addition, graft function has been similar in studies that have compared TacER and twice-daily tacrolimus (9, 16) . Second, donor age was higher (between 5 and 8 years) than in the Concept and Zeus studies, and CNI-related nephrotoxicity is determined in part by the quality of the graft (17) . Finally, in contrast to early elimination of CNIs, reduction in daily dose of tacrolimus did not improve renal function.
The main result of this study was that control of the alloresponse was poorer in the group with reduced exposure to tacrolimus. Indeed, we found a higher risk of acute cellular rejection; slightly increased subclinical inflammation at 12 mo after transplantation; and, most important, a higher risk of appearance of de novo DSAs in these patients. It is important to take into account that patients who were randomized were considered to be at very low immunological risk because strict selection criteria were applied during the first 4 mo, resulting in retention of patients without previous acute rejection and DSAs. This might explain the very low acute rejection rate between 4 and 12 mo in patients in whom the daily dose was maintained to obtain a TacER C 0 >7 lg/L, although steroids were withdrawn before randomization. It is known that the incidence of subclinical inflammation at 1 year after transplantation depends on the intensity of the immunosuppressive treatment and thus can change considerably according to the immunosuppressive strategy (18-21) ; however, the optimal TacER C 0 target remains to be defined. A retrospective analysis of TacER C 0 patients recorded during the first month after transplantation and at 6 mo in three clinical trials failed to define the optimal tacrolimus target to prevent BPAR, which occurred mainly within 1 year after transplantation (22) . Moreover, other recent studies have focused on different populations such as pretransplant immunized patients (23) or those who received lymphocyte-depleting agents (24) . Finally, our study is the first prospective study to show that trough tacrolimus concentrations should remain at the high end of the usual target levels. This result is clinically important because several studies have consistently shown that subclinical inflammation or rejection is associated with a decline in graft function (21, 25, 26) , development of IF/TA (19, 20) , and graft loss (27, 28) . The effects of preformed DSAs on graft outcome have also been clearly established (29) (30) (31) , and similar results have been reported recently on the impact of de novo DSAs in kidney transplant patients (3, 32, 33) . Consequently, we hypothesize that trough tacrolimus levels <7 lg/L at 4-12 mo after transplantation could result in poorer graft outcome.
It is nevertheless important to mention that other studies have shown that minimization of tacrolimus exposure could be safe and could improve graft function. Kamar et al, for example, reported that a significant reduction in tacrolimus exposure among 92 stable KTRs was associated with better graft eGFR after 6 mo when the dose of EC-MPS was increased to 1440 mg/day (34) . Another study that compared two tacrolimus-based regimens in stable KTRs did not show an increased risk of rejection (35) . In these two studies, KTRs were enrolled after the first year and sometimes after the fifth year following transplantation. Moreover, a large proportion of patients received steroids. Steroid therapy was also the main difference for patients randomized in the "low tacrolimus" arm of the Symphony study because the MMF dose was about 1.5 g/day during the second half-year after transplantation (36) , similar to the dose reported in our study at 4 mo and slightly higher than that reported at 12 mo. The results of our study should be interpreted in relation to the fact that we included steroid-free patients with MMF/EC-MPS dose between 1 and 1.5 g/day.
Importantly, BK viremia was not statistically different in the two groups in our study in which MMF/EC-MPS doses were similar; however, incidence was sixfold higher when TacER C 0 remained >7 lg/L, and close monitoring of BK virus reactivation is probably essential to limit the risk of BK nephropathy and to avoid counterbalancing the immunological advantage associated with maintaining TacER C 0 >7 lg/L. In contrast, the risk of PTDM after randomization was very similar in both groups, whereas almost all cases of PTDM occurred during the first 3 mo after transplantation. The protective effect of withdrawal of steroids should be taken into account when interpreting this result.
This study has certain limitations. First, about a third of patients in the initial cohort were not randomized; however, the aim of the stringent assessment of recipients was to limit the risk of BPAR after reduction of daily dose of tacrolimus and potentially to strengthen the message of the study. Alternatively, it could be argued that a renal biopsy performed before randomization might have identified subclinical rejection and prevented the risk of subsequent BPAR in patients for whom the daily dose of tacrolimus was reduced. However, the incidence of early subclinical rejection in patients receiving tacrolimus, MMF, and steroids is very low, and the value of a protocol biopsy remains disputed, especially in patients with low immunological risk (20) .
In conclusion, in case of steroid discontinuation and MMF/EC-MPS reduction, maintaining TacER C 0 >7 lg/L after the fourth month in the clinically stable KTR reduces the risk of acute rejection and appearance of DSAs without increasing renal toxicity.
